A phase-2 human clinical study showed that patients with nonalcoholic fatty liver disease (NAFLD) experienced a significant reduction in liver fat when receiving the combination of four metabolic activators aimed at improving the metabolic functions in the liver. The results of the study build on findings from preclinical data and human phase-1 clinical data.
